p2x7 (Alomone Labs)
Alomone Labs is a verified supplier 
Alomone Labs manufactures this product 
93
Structured Review
Alomone Labs
p2x7
P2x7, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p2x7/product/Alomone Labs
Average 93 stars, based on 2 article reviews
Price from $9.99 to $1999.99
P2x7, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p2x7/product/Alomone Labs
Average 93 stars, based on 2 article reviews
Price from $9.99 to $1999.99
p2x7 - by Bioz Stars,
2022-12
93/100 stars
Images
1) Product Images from "P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment"
Article Title: P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment
Journal: Cancers
doi: 10.3390/cancers12092342
Figure Legend Snippet: P2X7 receptor promotes invadopodial activity of extracellular matrix degradation. ( a ) 4T1 mouse mammary and MDA-MB-435s human cancer cells were grown on Matrigel™ containing DQ-BSA as a fluorogenic substrate for proteases, emitting red fluorescence when degraded. P2X7 receptor was immunodetected using a rabbit primary antibody against P2X7 protein and a secondary ant-rabbit IgG antibody conjugated to AF488. The right panel shows the fluorescence values for the two channels at the locations indicated by a blue arrow. Scale bar, 100 µm. ( b ) Invadopodia entrapped into a 2%-gelatin matrix were fractionated and separated from cytosol and membranes-enriched fractions. The quality of the fractions was assessed by western blotting after SDS-PAGE, using cytosolic (HSC70), membrane (caveolin-1, β-adaptin) and invadopodia (cathepsin B, cortactin, focal adhesion kinase) markers. P2X7 proteins were found to be present in the membrane fractions and enriched in the invadopodia fraction. This figure is representative of 5 independent experiments. The full image blots can be found in Figure S5 . ( c ) The invadopodial activity was assessed as being F-actin foci (green labelling, phalloidin-488) co-localised with focused proteolytic activities (red labelling, DQ-BSA proteolysis) from 4T1 cells grown for 24 h on Matrigel™ containing DQ-BSA in control condition (vehicle), or stimulated with 300 µM BzATP, in the presence and absence of 10 µM A438079. “Coloc” indicates co-localization of degradative activity and F-actin foci and appears as white pixels. Scale bar, 50 µm. ( d ) The number of degradation areas per cell was counted in 20 images, from five independent experiments. * indicates a statistically significant difference at p
Techniques Used: Activity Assay, Multiple Displacement Amplification, Fluorescence, Western Blot, SDS Page
Figure Legend Snippet: P2X7 antagonism slows mammary tumour growth. ( a ) In vivo mouse experiments assessing the effects of treatments with two P2X7 antagonist (A438079 or AZ10606120) on primary tumour growth, in which cancer cells and host organisms both express the P2rx7 gene. ( b ) primary mammary tumour growth represented as a function of the duration of the treatment depending on antagonist treatments (A438079 or AZ10606120) compared to the injection of vehicle. ( c – e ) A Gompertz model was used to assess mammary tumour growth as a function of time for ( c ), vehicle group, ( d ), A438079 and ( e ), AZ10606120. Black, red and blue dots represent individual tumour volumes of these respective categories, blue areas are 90% model prediction intervals and lines are the median tumour growth. Estimated mean (inter-individual standard deviation) of model parameters were k growth = 0.64 day-1 (39%), V max = 1.620 mm 3 (64%), EFF = 0.52 (82%) and γ = 0.17 (–). This analysis showed that tumour volume doubled in a mean time of 0.64 day, that the mean maximum tumour volume was 1.620 mm 3 and that tumour growth was twice slower in the presence of A438079 or AZ10606120 treatment ( p
Techniques Used: In Vivo, Injection, Standard Deviation
Figure Legend Snippet: P2X7 receptor in mammary cancer cells enhances primary tumour growth and metastatic development in vivo. ( a ) P2rx7 mRNA expression levels assessed by RT-qPCR in CTL, Crispr#1 and Crispr#2 cell lines, expressed relatively to 4T1 cells. * indicated a statistically significant difference from CTL cells at p
Techniques Used: In Vivo, Expressing, Quantitative RT-PCR, CRISPR
Figure Legend Snippet: P2X7 receptor stimulation promotes the acquisition of a mesenchymal phenotype. ( a ) F-actin cytoskeleton was visualized using phalloidin-488 in 4T1 cells stimulated with 300 µM BzATP at the time indicated. Rapid morphological changes appear as rapidly as after 6 min stimulation. Scale bar, 25 µm. ( b ) The number of new filopodia per cell was counted per hour in cells transfected with the LifeAct plasmid and studied in the presence of 300 µM BzATP, in the presence or absence of 10 µM A438079. * indicates a statistically significant difference at p
Techniques Used: Transfection, Plasmid Preparation
2) Product Images from "Atheroprone flow activates inflammation via endothelial ATP-dependent P2X7-p38 signalling"
Article Title: Atheroprone flow activates inflammation via endothelial ATP-dependent P2X7-p38 signalling
Journal: Cardiovascular Research
doi: 10.1093/cvr/cvx213
Figure Legend Snippet: P2X7 receptor activity occurs exclusively in HUVEC under atheroprone flow. Representative single cell ATP-induced calcium responses in atheroprotected ( A ) or atheroprone ( B, C ) flow conditioned HUVEC after thapsigargin pre-treatment ± the P2X7 inhibitor 10 µM A438079 (P2X7i) or siRNA control and P2X7 knockdown ( C ) and analysed by measuring the average area under the curve ( n = 4, 175 cells per donor, * indicates P ≤ 0.05 using a paired t -test). Values are mean ± S.E.M.
Techniques Used: Activity Assay
Figure Legend Snippet: Expression of ATP-gated P2X7 receptors is enhanced under atheroprone flow. ( A ) Western blot and densitometry of P2X7 in flow conditioned HUVEC using the ibidi flow system ( n = 6, ** indicates P ≤ 0.01 using a paired t -test). P2X7 is shown by an arrow, validated by P2X7 knockdown, shown in Supplementary material online , Figure 4 B. ( B ) Western blot and densitometry of P2X7 in flow conditioned HUVEC using the orbital shaker system ( n = 4, ** indicates P ≤ 0.01 using a paired t -test). ( C ) Representative en face immunostaining for P2X7 (red) on wildtype C57BL/6 mice at atheroprotective (outer curvature) and atheroprone (inner curvature) regions of the aorta (scale = 25 µm). Endothelial cells were identified by staining with CD31 (green) and cell nuclei were stained using TO-PRO (blue). P2X7 expression was analysed by measuring the relative fluorescent intensity at sites protected or prone to atherosclerosis. Surface expression was measured by measuring P2X7 fluorescence at sites co-localized with the endothelial cell surface marker CD31. Relative fluorescent intensities for P2X7 were corrected against the relative fluorescent intensity of IgG performed on the descending aorta ( n = 5, * indicates P ≤ 0.05 and *** indicates P ≤ 0.001 using a paired t -test). Values are mean ± S.E.M.
Techniques Used: Expressing, Western Blot, Immunostaining, Mouse Assay, Staining, Fluorescence, Marker
Figure Legend Snippet: P2X7 regulates E-selectin expression at sites susceptible to atherosclerosis in vivo . Representative en face immunostaining for E-selectin (red) on wildtype or P2X7 −/− BALB/c mice at atheroprotective (outer curvature) and atheroprone (inner curvature) sites of the aorta ( n = 4–5) (scale = 25 µm). Endothelial cells were identified by staining with CD31 (green) and cell nuclei were stained using TO-PRO (blue). E-selectin expression was analysed by measuring the relative fluorescent intensity at sites of protected or prone to atherosclerosis ( n = 4–5, * indicates P ≤ 0.05, ** indicates P ≤ 0.01 and *** indicates P ≤ 0.001 using a two-way ANOVA). Relative fluorescent intensities for P2X7 were corrected against the relative fluorescent intensity of IgG. Values are mean ± S.E.M.
Techniques Used: Expressing, In Vivo, Immunostaining, Mouse Assay, Staining
Figure Legend Snippet: Atheroprone flow mediated inflammatory signalling is regulated by P2X7 responses. qPCR analysis of E-selectin ( A ) and IL-8 ( B ) in HUVEC conditioned with atheroprotective or atheroprone flow using the ibidi system ± the P2X7 inhibitor 10 µM A438079 (P2X7i) ( n = 5, * indicates P ≤ 0.05 using a two-way ANOVA). ( C ) IL-8 release measured by ELISA in the supernatant of HUVEC conditioned under atheroprotective or atheroprone flow using the ibidi system ± the P2X7 inhibitor 10 µM A438079 (P2X7i) ( n = 9, * indicates P ≤ 0.05, *** indicates p =
Techniques Used: Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay
